Latest AI and machine learning research in alzheimer's disease for healthcare professionals.
The specific neuroanatomy of mild cognitive impairment (MCI) is obscured by its clinical heterogeneity and confounding effects from normative variation. This problem is compounded by the inability of conventional neuroimaging methods to disentangle these overlapping influences. Leveraging data from the Beijing Aging Brain Rejuvenation Initiative (BABRI, n = 918) and the Alzheimer's Disease Neuroim...
Patients with spontaneous intracerebral hemorrhage (sICH) are at high risk for venous thromboembolism (VTE), a complication strongly associated with adverse clinical outcomes. While prophylactic anticoagulation has been shown to effectively reduce VTE incidence, significant uncertainty remains regarding its safety and the optimal timing of initiation. This article comprehensively reviews key aspec...
The drug development for central nervous system (CNS) disorders, particularly neurodegenerative diseases, such as Alzheimer's disease, Parkinson's dis...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and substantial brain atrophy. Early and accur...
Extensive studies have shown that cerebrovascular dysfunction is a critical factor in the onset and progression of Alzheimer's disease (AD). Neurovasc...
Brain-machine interfaces (BMIs), which serve as revolutionary tools for neural recording, modulation, and rehabilitation, are highly dependent on the ...
BACKGROUND: With the growing aging population, technology that supports independent living is increasingly important. Web search systems are well esta...
Exhaled volatile organic compounds (VOCs) have been investigated in some diseases, including cognitive impairment, in pilot studies. The present study...
OBJECTIVE: To assess the effectiveness of robot-based interventions in improving depressive symptoms among older adults with cognitive impairment, and...
BACKGROUND: Effective screening and cohort enrichment remain major challenges in clinical trials for Alzheimer's disease (AD), where traditional diagn...
BACKGROUND: Treatment-as-usual (TAU) conditions are intended to reflect the support typically received in routine treatment settings. For digital ment...
Tau aggregation and hyperphosphorylation are key pathological hallmarks and early diagnostic biomarkers of Alzheimer's disease (AD). However, the simu...
Alzheimer's Disease (AD) detection is essential for timely treatment and better patient care. Magnetic Resonance Imaging (MRI) is a technique in which...
BACKGROUND: Histone deacetylases (HDACs) regulate neuroprotection; however, Trichostatin A (TSA), an HDAC inhibitor, lacks clear molecular mechanisms ...
Alzheimer's disease (AD) and mild cognitive impairment (MCI) are two dementia-related brain illnesses that are prevalent among elders in the twenty-fi...
Predicting the likelihood of developing Alzheimer's disease (AD) dementia in at-risk individuals is important for the design of and optimal recruitmen...
Brain age is a valuable neuroimaging-based biomarker for assessing brain health, typically estimated using machine learning (ML) models. However, ML a...
BACKGROUND: Dementia presents complex challenges for causal inference due to its multifactorial aetiology and slow, heterogeneous progression. Randomi...
Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key enzyme in amyloid-β generation and remains an important target in Alzheimer's d...